Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds

This study has been terminated.
(Due to slow recruitment)
Sponsor:
Collaborator:
TransCom Global Ltd. (CRO)
Information provided by (Responsible Party):
Regenera Pharma Ltd
ClinicalTrials.gov Identifier:
NCT01429519
First received: September 4, 2011
Last updated: October 15, 2012
Last verified: October 2012
  Purpose

The study objectives are to evaluate safety and efficacy of topical administration of RPh201 oil solution (botanical extract) for treatment of patients with hard to heal chronic ulcerated wounds.


Condition Intervention Phase
Chronic Wound
Drug: RPh201, botanical drug product
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS

Further study details as provided by Regenera Pharma Ltd:

Primary Outcome Measures:
  • To determine the safety use of RPh201 administered topically three times a week during an overall treatment period of up to 4 weeks, with 52 days follow-up [ Time Frame: 90 days ] [ Designated as safety issue: Yes ]
    • Safety evaluation - To demonstrate safety using the RPh201 oil solution in terms of skin irritation score to be less than 2 for erythema /edema individual subject's results or less then 1.9 for Primary Irritation Index (PII) category (see section 6.5.2 and APPENDIX 2) .
    • Safety evaluation - To demonstrate safety of using RPh201 oil solution in terms of type and severity of adverse events.


Secondary Outcome Measures:
  • To obtain preliminary data on the efficacy of RPh201 on improving wound status in patients with hard to heal chronic ulcerated wounds [ Time Frame: 90 days ] [ Designated as safety issue: No ]
    • Evaluation of the correlation between the treatment period and changes in wound area size.
    • Assessment of wound closure state in terms of % Non-viable area, % granulation tissue appearance,
    • Assessment of wound closure state in terms of time to wound closure.
    • Assessment of pain based on a pain analog scale of 1-10.


Estimated Enrollment: 15
Study Start Date: December 2011
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Drug: RPh201, botanical drug product
topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day

Detailed Description:

The study objectives are to evaluate safety and efficacy, of topical administration of RPh201 for treatment of patients with hard to heal wounds.

This is to include:

  • Safety evaluation of RPh201 (botanical extract) formulated as an oil solution administered topically three times per week during an overall treatment period of up to 4 weeks in patients with hard to heal wounds.
  • Efficacy assessment of wound improvement following the use of RPh201 oil solution (botanical extract) administered topically three times per week during an overall treatment period of up to 4 weeks and at the follow-up visit at 3 months after end of treatment in patients with hard to heal wounds
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants, either men or women are ≥ 18 years of age.
  2. Patients must have at least one hard to heal wound of different etiologies (venous insufficiency, lymphatic insufficiency, neuropathic wounds or diabetic ulcers, post- operative and post-traumatic chronic wounds) located on the leg shin or foot.
  3. The wound is refractive to healing at least 4 weeks prior to treatment, although treated by routine practice.
  4. Wound area size is in the range of: 3 - 36 square centimeters.
  5. Patients defined as grade C or above on the granulometer scale (see section 6.5.1).
  6. Participants understand the nature of the procedure and provide written informed consent prior to any study procedure.
  7. Women of child bearing potential must use adequate birth-control precautions.

Exclusion Criteria:

  1. Clinically significant arterial vascular disease with ABI index <0.45 if the peripheral pulse is not palpable, or flatted PVR in case of non palpable arteries.
  2. Clinical evidence for presence of infection in the soft tissue, joint and/or bone (osteomyelitis).
  3. Wound has Non-viable tissue which covers more than 50% of the wound area.
  4. Patients with skin disorders unrelated to the ulcer that are presented adjacent to the wound.
  5. The wound penetrates into deep organs and involves bone, tendon or joint
  6. Wound with sinus tracts
  7. Patients are receiving, or have received within one month prior to enrollment any treatment known to impair wound healing, including but not limited to: immuno-suppressive drugs, cytotoxic agents, radiation therapy and chemotherapy.
  8. Treatment with a dressing containing growth factors or other biological dressings within 15 days, prior to the screening visit.
  9. Patients that have a history of alcohol or drug abuse within the last two years.
  10. Female patients who are pregnant or nursing, or of childbearing potential and are not using adequate contraception.
  11. Participation in another clinical trial within 30 days prior to the Screening Visit or during this study.
  12. Clinically significant and/or uncontrolled condition or other significant medical disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01429519

Locations
Israel
High Risk Foot Clinic - Maccabi Health Services
Tel-Aviv, Israel
Sponsors and Collaborators
Regenera Pharma Ltd
TransCom Global Ltd. (CRO)
Investigators
Principal Investigator: Eran Tamir, Dr. High Risk Foot Clinic - Maccabi Health Services Tel Aviv
  More Information

No publications provided

Responsible Party: Regenera Pharma Ltd
ClinicalTrials.gov Identifier: NCT01429519     History of Changes
Other Study ID Numbers: RGN-WH-001
Study First Received: September 4, 2011
Last Updated: October 15, 2012
Health Authority: Israel: Ministry of Health

Keywords provided by Regenera Pharma Ltd:
chronic wound
ulcerated wound
venous insufficiency
lymphatic insufficiency
neuropathic wound
diabetic ulcer
post- operative
post-traumatic chronic wound

Additional relevant MeSH terms:
Ulcer
Pathologic Processes

ClinicalTrials.gov processed this record on April 22, 2014